News und Analysen
1 Top Dividend Growth Stock to Buy on the Dip
Biotech giant Amgen (NASDAQ: AMGN) isn't having a great year. Its shares are down by 12% since 2023 started, and the company has faced several issues recently that have harmed its financial results
1 Top Dividend Growth Stock to Buy on the Dip
Biotech giant Amgen (NASDAQ: AMGN) isn't having a great year. Its shares are down by 12% since 2023 started, and the company has faced several issues recently that have harmed its financial results
1 Top Dividend Growth Stock to Buy on the Dip
Biotech giant Amgen (NASDAQ: AMGN) isn't having a great year. Its shares are down by 12% since 2023 started, and the company has faced several issues recently that have harmed its financial results
3 Fantastic Growth Stocks to Buy in August
What's a great thing to do during the hot month of August? One option is to find somewhere cool. Another is to invest in stocks that could deliver their own kind of sizzle.
We asked three Motley
Why Shares of Mesoblast Are Plunging Friday
Shares of Mesoblast (NASDAQ: MESO) were down more than 61% as of 2:15 p.m. on Friday. The pharmaceutical stock is down more than 54% so far this year.
Mesoblast focuses on allogeneic cellular
Why Natera Stock Is Soaring Today
Shares of Natera (NASDAQ: NTRA) were soaring 18.7% higher at 11:04 a.m. ET on Friday. The big gain came after the DNA testing company announced its second-quarter results following the market close
If You Had Invested $5,000 in Amgen in 2013, This Is How Much You Would Have Today
Few other investment vehicles have arguably done more to enrich investors than the U.S. stock market. For example, A $5,000 investment in the S&P 500 index executed 10 years ago in 2013 would be
If You Had Invested $5,000 in Amgen in 2013, This Is How Much You Would Have Today
Few other investment vehicles have arguably done more to enrich investors than the U.S. stock market. For example, A $5,000 investment in the S&P 500 index executed 10 years ago in 2013 would be
If You Had Invested $5,000 in Amgen in 2013, This Is How Much You Would Have Today
Few other investment vehicles have arguably done more to enrich investors than the U.S. stock market. For example, A $5,000 investment in the S&P 500 index executed 10 years ago in 2013 would be
Does Abbott Laboratories' Dividend Make It a Buy?
When you're in the market for dividend income, it's important to keep your eye on the long term. An attractive payout today isn't worth much if the company might be forced to reduce or cut its
Want $1,500 in Annual Passive Income? Invest This Much in Viatris Stock Each Month for 5 Years
Especially if you're living on a fixed income, being able to bring in even $1,500 in extra money each year via dividends can be a big change for the better. But it's often difficult to figure out
Want $1,500 in Annual Passive Income? Invest This Much in Viatris Stock Each Month for 5 Years
Especially if you're living on a fixed income, being able to bring in even $1,500 in extra money each year via dividends can be a big change for the better. But it's often difficult to figure out
Is AbbVie Stock a Buy for Income Investors?
There are very few constants in life. But bills coming in on a routine basis is one of them. This is what makes income investing an appealing strategy for investors to generate the cash flow
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Dynavax Technologies (DVAX) Q2 2023 Earnings Call Transcript
Image source: The Motley Fool.
Dynavax Technologies (NASDAQ: DVAX)Q2 2023 Earnings CallAug 03, 2023, 4:30 p.m. ET
Operator
Source Fool.com
Geron (GERN) Q2 2023 Earnings Call Transcript
Image source: The Motley Fool.
Geron (NASDAQ: GERN)Q2 2023 Earnings CallAug 03, 2023, 4:30 p.m. ET
Aron Feingold
Source Fool.com
EQS-News: Carl Zeiss Meditec achieves further strong revenue growth after nine months of fiscal year 2022/23 with continued high strategic investments
EQS-News: Carl Zeiss Meditec achieves further strong revenue growth after nine months of fiscal year 2022/23 with continued high strategic investments
Why Coherus BioSciences Stock Popped Today
Shares of Coherus BioSciences (NASDAQ: CHRS) soared 17.7% on Thursday, according to data provided by S&P Global Market Intelligence, after the biotech company announced better-than-expected
EQS-News: Invitation to MorphoSys’ Second Quarter and First Half 2023 Financial Results Conference Call on August 10, 2023
EQS-News: Invitation to MorphoSys’ Second Quarter and First Half 2023 Financial Results Conference Call on August 10, 2023
Cigna Group (CI) Q2 2023 Earnings Call Transcript
Image source: The Motley Fool.
Cigna Group (NYSE: CI)Q2 2023 Earnings CallAug 03, 2023, 8:30 a.m. ET
Operator
Source Fool.com
Humana Foundation Announces 2023 Scholarship Awards
The Humana Foundation, the philanthropic arm of Humana Inc. (NYSE: HUM) for the past 41 years, today announced 81 winners of college scholarships awarded through the Humana Foundation Scholarship
Got $5,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond
The stock market is roaring back in 2023 following a downturn. However, the year hasn't been kind to every company. For instance, drugmakers AbbVie (NYSE: ABBV) and Axsome Therapeutics (NASDAQ:
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc